How often is testosterone injected for TRT?

Every vial at a glance.

Each row is a concentration; units are the dose over the concentration, times 100, on a U-100 syringe.
ConcentrationDraw per dose
100 mg/mL100 mg/mL: 50 mg is 0.5 mL, the 50 mark, 100 mg is 1 mL, the 100 mark
200 mg/mL200 mg/mL: 50 mg is 0.25 mL, the 25 mark, 100 mg is 0.5 mL, the 50 mark

Jump to a vial 100 mg/mL 200 mg/mL

The US Depo-Testosterone (cypionate) and Hikma enanthate labels give 50 to 400 mg every two to four weeks for replacement in hypogonadal men, while the Xyosted label starts its weekly subcutaneous enanthate at 75 mg once a week; a review in Cureus (Farzam) lists twice-weekly, three-times-weekly, every-other-day and daily injections as optional tools, not universal standards.1234

What the labels give for each product

ProductLabel dose and interval
Depo-Testosterone (cypionate)50 to 400 mg every two to four weeks for replacement in hypogonadal men, intramuscular1
Testosterone enanthate (Hikma)50 to 400 mg every 2 to 4 weeks as replacement in male hypogonadism, intramuscular2
Xyosted (enanthate, under the skin)75 mg once a week to start, in the abdominal region3
Sustanon 250 (UK summary)One 1 mL injection per 3 weeks, described as adequate in adults (incl. elderly), by deep intramuscular injection5

The Hikma enanthate label calls injections more often than every two weeks rarely indicated, and says total doses above 400 mg a month are in general not required because of the preparation's prolonged action.2 The Xyosted label adjusts the dose in 25 mg steps by trough total testosterone, measured 7 days after the latest dose: down 25 mg at a trough of ≥650 ng/dL and up 25 mg at a trough of <350 ng/dL.3

What happens to blood levels between injections

In 11 hypogonadal men (Nankin, 1987), a 200 mg intramuscular cypionate injection raised serum testosterone threefold, peaking on days 2 to 5, and levels declined to basal by days 13 to 14.6 In a 24-week randomised study of sixty-six adult hypogonadal men (Dobs, 1999), 33 per group, comparing a testosterone transdermal system (Androderm, two 2.5-mg systems applied nightly) with 200 mg intramuscular enanthate every 2 weeks, the injections produced supraphysiological testosterone, bioavailable testosterone and estradiol for several days after each injection.7

Weekly, twice weekly or daily

A single-author review in Cureus (Farzam), not a guideline, says larger injections at longer intervals give higher early peaks and lower late troughs in serum testosterone.4 It says weekly dosing is often a reasonable and effective schedule, and many patients do well with it.4 It lists twice-weekly, three-times-weekly, every-other-day and daily injections as optional tools, not universal standards, that lower the amount of testosterone delivered at one time, though more injections can reduce adherence.4

Where the pattern suggests fluctuation rather than under-replacement, the review says spreading the same or a lower weekly amount over more frequent doses can generally be considered before raising the total dose.4 The review says few trials directly compare these schedules for patient-reported outcomes, and that current evidence does not support one universal injection schedule.4 The evidence search found no label, guideline or trial that compares these schedules head to head. No label in this guide covers daily or every-other-day subcutaneous cypionate or enanthate, and the evidence search found no trial of them; of the sources here, only the Cureus review describes these as optional schedules.4

Does injecting under the skin change the interval?

The Xyosted label describes a 52-week open-label study (NCT02159469) of once-weekly subcutaneous dosing in 150 adult males with hypogonadism.3 In 234 hypogonadal men (Choi, 2022), 100 mg weekly as intramuscular cypionate or as a subcutaneous enanthate autoinjector both raised trough total testosterone at 12 weeks, and the type of treatment was not associated with total testosterone levels (p=0.057), but the autoinjector was independently associated with lower post-therapy estradiol and hematocrit than intramuscular cypionate after adjusting for significant covariates.8

In 11 transgender men already on weekly subcutaneous cypionate (McFarland), mean total testosterone remained within the normal range throughout the 7-day interval between doses.9 In their introduction, describing intramuscular injection, the authors say that while on average serum testosterone stays within the target range, with a dosing interval greater than 1 week levels rise above the normal range within the first 48 hours after the injection and fall below it in the days before the next dose.9 The participants were transgender men; the authors anticipate that the results can be extended to hypogonadal men, and the evidence search found no pharmacokinetic study of subcutaneous cypionate in hypogonadal men.9

Schedules people set up in Milligram

Of the people who logged testosterone enanthate in Milligram, 39% set up a twice-a-week schedule.10 Another 34% set up an every-other-day schedule.10 16% set up a once-a-day schedule.10 8% set up a once-a-week schedule.10

Of the people who logged testosterone cypionate, 36% set up a twice-a-week schedule.10 Another 33% set up an every-other-day schedule.10 18% set up a once-a-day schedule.10 11% set up a once-a-week schedule.10

From mg to mL to syringe units

The cypionate label lists 100 mg/mL and 200 mg/mL strengths.1 Of the people who logged cypionate, 6% set up 100 mg at 50 units.10

In the worked example, 100 mg of testosterone cypionate from the label's 200 mg/mL strength1 is 0.5 mL, which is 50 units on a U-100 syringe.

How the logged figures are counted

Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

References

  1. Pfizer (Pharmacia & Upjohn), via DailyMed. Depo-Testosterone (testosterone cypionate) injection, US prescribing information. 2025. dailymed.nlm.nih.gov
  2. Hikma, via DailyMed. Testosterone enanthate injection (Hikma), US prescribing information. dailymed.nlm.nih.gov
  3. Antares Pharma, via DailyMed. Xyosted (testosterone enanthate) injection, US prescribing information. 2025. dailymed.nlm.nih.gov
  4. Cureus (Farzam). Individualizing Injectable Testosterone Replacement Therapy in Primary Care: Pharmacokinetics, Symptom Stability, Safety Monitoring, and Injection Frequency. 2026. ebi.ac.uk
  5. electronic medicines compendium (emc), UK. Sustanon 250, 250mg/ml solution for injection, Summary of Product Characteristics. medicines.org.uk
  6. Fertility and Sterility (Nankin), PubMed abstract. Hormone kinetics after intramuscular testosterone cypionate. 1987. eutils.ncbi.nlm.nih.gov
  7. J Clin Endocrinol Metab (Dobs et al.), PubMed abstract. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate. 1999. eutils.ncbi.nlm.nih.gov
  8. Journal of Urology (Choi et al.), PubMed abstract. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. 2022. eutils.ncbi.nlm.nih.gov
  9. Journal of the Endocrine Society (McFarland et al.). Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. 2017. ebi.ac.uk
  10. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted